
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical suspension containing thiamine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing thiamine are listed in injection form. It is also a component of FDA-approved kits.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Thiamine hydrochloride is a form of vitamin B1, given by injection or taken by mouth, that a pharmacy may compound when a prescriber orders it.
Thiamine, or vitamin B1, is a water-soluble B vitamin found in foods such as whole grains, pork, beans and fortified cereals. In the body it is converted to thiamine pyrophosphate, a coenzyme the body needs to turn carbohydrates and other nutrients into energy. Prescription thiamine hydrochloride injection, approved as a generic (ANDA), is labeled for thiamine deficiency or beriberi, for cases needing rapid restoration such as Wernicke's encephalopathy, when giving IV dextrose to people with marginal thiamine status, and for established deficiency when thiamine cannot be taken by mouth. Oral thiamine tablets and capsules are sold over the counter as dietary supplements. A prescriber might order thiamine compounded in a strength or form that is not manufactured, without preservatives or other excipients found in commercial products, or combined with other ingredients. Compounded preparations are not FDA-approved and require a prescription.
Thiamine injection labels carry no boxed warning but warn that serious allergic and anaphylactic reactions, including deaths, have occurred after IV or IM injection, especially after repeated doses. Do not use it if you have had a reaction to thiamine or any ingredient in the product. Some injections contain aluminum, which can build up to harmful levels in people with kidney problems and in premature infants. Side effects reported include warmth, itching, hives, weakness, sweating, nausea, restlessness and tenderness at an IM injection site. StatPearls notes that long-term high-dose furosemide and the antibiotic erythromycin can lower thiamine levels, and patiromer can reduce absorption of oral thiamine. The injection label says to use it in pregnancy only if clearly needed and to use caution in nursing mothers; StatPearls adds that infants breastfed by mothers with low thiamine intake can become deficient. Talk to your prescriber or pharmacist about side effects.
Thiamine combines with ATP to form thiamine pyrophosphate (cocarboxylase), a coenzyme for decarboxylation of pyruvate and alpha-keto acids and a cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and erythrocyte transketolase (label; StatPearls). Per the Fresenius Kabi label, absorption after IM injection is rapid and complete; it distributes to all tissues, with the highest concentrations in liver, brain, kidney and heart; excess is excreted in urine. StatPearls describes active small-intestine absorption at nutritional intakes and passive diffusion at pharmacologic doses. Labeled indications (thiamine hydrochloride injection, ANDA): thiamine deficiency and beriberi, Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease from deficiency, neuritis of pregnancy with severe vomiting, IV dextrose in marginal thiamine status, and deficiency with inability to take oral thiamine. Give thiamine before glucose in deficient patients (StatPearls). For suspected hypersensitivity, the label describes an intradermal test dose with observation and readiness to treat anaphylaxis. Serum thiamine is not a reliable marker; StatPearls describes erythrocyte transketolase activity or whole-blood thiamine pyrophosphate. Suspect multiple vitamin deficiencies. Thiamine is not a controlled substance. Dosing is per prescriber.
Wash your hands. Shake the bottle well before every use so the medication is evenly mixed. Apply the amount on your label to clean, dry skin with the applicator or a cotton swab and let it dry. Keep it away from the eyes. Wash your hands afterward.
Topical suspensions are aqueous. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Keep the bottle closed, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)